John McGee, Ph.D.

Scientific Co-Founder and Senior Vice President, Platform Technology

John McGee brings to Parabilis Medicines more than 15 years of experience in developing and applying new discovery and optimization technologies for helically constrained (Helicon) peptide therapeutics.

Prior to joining Parabilis Medicines, John was a postdoctoral research fellow at Harvard University, where he worked in the laboratory of Dr. Greg Verdine. At Harvard, he performed foundational work on both the de novo screening and multiplexing platforms that now form the core of Parabilis Medicines’ discovery engine. These studies also led to the development of the tandem paired-helix Griptide platform, now licensed by Parabilis Medicines; John made the key discovery of Griptides that bind a range of active RAS isoforms and oncogenic mutants with picomolar affinity.

John holds a B.S. in chemistry from Stanford University, where he worked in the laboratory of Dr. Eric Kool, and a Ph.D. in biochemistry from Harvard University, where he studied with Dr. Greg Verdine.